Csóka M - Search Results

1

Characteristic mTOR activity in Hodgkin-lymphomas offers a potential therapeutic target in high risk disease--a combined tissue microarray, in vitro and in vivo study.

Márk Á, Hajdu M, Váradi Z, Sticz TB, Nagy N, Csomor J, Berczi L, Varga V, Csóka M, Kopper L, Sebestyén A. Márk Á, et al. Among authors: csoka m. BMC Cancer. 2013 May 22;13:250. doi: 10.1186/1471-2407-13-250. BMC Cancer. 2013. PMID: 23693095 Free PMC article.

2

Treatment of pediatric non-Hodgkin lymphoma in Hungary: 15 years experience with NHL-BFM 90 and 95 protocols.

Müller J, Csóka M, Jakab Z, Ponyi A, Erlaky H, Kovács G. Müller J, et al. Among authors: csoka m. Pediatr Blood Cancer. 2008 Mar;50(3):633-5. doi: 10.1002/pbc.21144. Pediatr Blood Cancer. 2008. PMID: 17366531

3

[Lymphomas in adolescents: are childhood lymphoma therapy protocols suitable for this patient group?].

Bence Z, Kovács G, Jakab Z, Csóka M, Müller J. Bence Z, et al. Among authors: csoka m. Magy Onkol. 2008 Dec;52(4):357-62. doi: 10.1556/MOnkol.52.2008.4.4. Magy Onkol. 2008. PMID: 19068463 Hungarian.

4

Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL).

Nemes K, Sebestyén A, Márk A, Hajdu M, Kenessey I, Sticz T, Nagy E, Barna G, Váradi Z, Kovács G, Kopper L, Csóka M. Nemes K, et al. Among authors: csoka m. PLoS One. 2013;8(4):e59335. doi: 10.1371/journal.pone.0059335. Epub 2013 Apr 3. PLoS One. 2013. PMID: 23573198 Free PMC article.

5

[Diagnosis and treatment of childhood soft tissue sarcomas].

Bánusz R, Váradi Z, Varga E, Jakab Z, Garami M, Csóka M. Bánusz R, et al. Among authors: csoka m. Magy Onkol. 2014 Mar;58(1):59-64. Epub 2014 Mar 1. Magy Onkol. 2014. PMID: 24712008 Free article. Review. Hungarian.

6

Expression of certain leukemia/lymphoma related microRNAs and its correlation with prognosis in childhood acute lymphoblastic leukemia.

Nemes K, Csóka M, Nagy N, Márk Á, Váradi Z, Dankó T, Kovács G, Kopper L, Sebestyén A. Nemes K, et al. Among authors: csoka m. Pathol Oncol Res. 2015 Jul;21(3):597-604. doi: 10.1007/s12253-014-9861-z. Epub 2014 Nov 12. Pathol Oncol Res. 2015. PMID: 25388103 Free article.

7

Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.

Nagy N, Hajdu M, Márk Á, Király PA, Tóth M, Dankó T, Csóka M, Sebestyén A. Nagy N, et al. Among authors: csoka m. Tumour Biol. 2016 Oct;37(10):13695-13704. doi: 10.1007/s13277-016-5272-y. Epub 2016 Jul 29. Tumour Biol. 2016. PMID: 27473087

8

Primary alveolar rhabdomyosarcoma of the bone: two cases and review of the literature.

Balogh P, Bánusz R, Csóka M, Váradi Z, Varga E, Sápi Z. Balogh P, et al. Among authors: csoka m. Diagn Pathol. 2016 Oct 18;11(1):99. doi: 10.1186/s13000-016-0552-9. Diagn Pathol. 2016. PMID: 27756397 Free PMC article.

9

Effective BRAF inhibitor vemurafenib therapy in a 2-year-old patient with sequentially diagnosed Langerhans cell histiocytosis and Erdheim-Chester disease.

Váradi Z, Bánusz R, Csomor J, Kállay K, Varga E, Kertész G, Csóka M. Váradi Z, et al. Among authors: csoka m. Onco Targets Ther. 2017 Jan 24;10:521-526. doi: 10.2147/OTT.S121615. eCollection 2017. Onco Targets Ther. 2017. PMID: 28182116 Free PMC article.

10

Juvenile myelomonocytic leukaemia presentation after preceding juvenile xanthogranuloma harbouring an identical somatic PTPN11 mutation.

Bátai B, Krizsán S, Gángó A, Hegyi L, Csóka M, Erdélyi DJ, Csomor J, Kállay K, Bödör C. Bátai B, et al. Among authors: csoka m. Pediatr Blood Cancer. 2020 Sep;67(9):e28368. doi: 10.1002/pbc.28368. Epub 2020 Jun 18. Pediatr Blood Cancer. 2020. PMID: 32558336 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89 results

Search Page

Filters